Millons are impacted by hearing loss.
We're seeking to restore the clarity they've lost.

Learn More

Reimagining Treatments for Hearing Loss

More than 40 million people in the U.S. struggle with sensorineural hearing loss, the most common type of hearing loss. This condition affects more than just hearing; it’s about understanding, confidence, and connection. Individuals may have difficulty speaking on the phone, struggle in certain jobs, and become socially isolated. What may start as a minor inconvenience can get progressively worse.

Untreated, individuals face associated risk of depression and dementia. Current treatments can help make sounds louder, but we’re leading the creation of the first-ever disease-modifying therapy for sensorineural hearing loss — one that aims to restore hearing function and enhance the ability to clearly understand speech.

Learn More

Building a Novel Regenerative Medicine Approach

We are pioneers of Progenitor Cell Activation (PCA). Similar to stem cells, progenitor cells are pre-programmed to create specific cell types. In the inner ear, for example, they generate the sensory hair cells that enable us to hear.

We believe this approach can be applied to a range of tissues and organs affected by degenerative disease. We’re creating a new class of therapeutics that aims to activate these progenitor cells using small molecules that do not alter genes and which can be delivered with less complexity than current regenerative medicines.

Learn More

Understanding Speech Intelligibility

News & Insights

INSIGHT

August 23, 2021

Episode 2 of the Overheard at Frequency podcast, with guest Barbara Kelley of the Hearing Loss Association of America (HLAA).

Listen Now

NEWS

September 8, 2021

Frequency Therapeutics to Present at Upcoming Investor Conferences

Read More

NEWS

August 12, 2021

Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results

Read More

Join Our Team

Learn more about Frequency, our team and culture, and opportunities to grow your career.

Learn More